Cour Pharma

Chicago, United States Founded: 2013 • Age: 13 yrs
Biotech nanoparticles are developed for immune disease treatments.
Request Access

About Cour Pharma

Cour Pharma is a company based in Chicago (United States) founded in 2013.. Cour Pharma has raised $135.2 million across 6 funding rounds from investors including Pfizer, Roche and Bristol-Myers Squibb. The company has 31 employees as of December 31, 2021. Cour Pharma offers products and services including CNP-103 and CNP-106. Cour Pharma operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.

  • Headquarter Chicago, United States
  • Employees 31 as on 31 Dec, 2021
  • Sectors
    Healthcare
    Technology
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Technology → Quantum & Emerging Technologies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $135.2 M (USD)

    in 6 rounds

  • Latest Funding Round
    $105 M (USD), Series A

    Jan 30, 2024

  • Investors
    Pfizer

    & 6 more

  • Employee Count
    31

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cour Pharma

Cour Pharma offers a comprehensive portfolio of products and services, including CNP-103 and CNP-106. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Therapy to induce tolerance for type 1 diabetes using nanoparticles

Treatment for myasthenia gravis via immune-modifying nanoparticles

People of Cour Pharma
Headcount 10-50
Employee Profiles 8
Board Members and Advisors 6
Employee Profiles
People
John J. Puisis
Co-Founder & President & CEO
People
Brian C. Bock
CFO
People
Robert Hodge
VP of Technical Development
People
Sarah Longoria
Chief People Officer

Unlock access to complete

Board Members and Advisors
people
Kari Nadeau
Advisor
people
Ciarán P. Kelly
Advisor
people
John Fung
Advisor
people
M. Eric Gershwin
Advisor

Unlock access to complete

Funding Insights of Cour Pharma

Cour Pharma has successfully raised a total of $135.2M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $105 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Series A — $105.0M
  • First Round

    (28 Jan 2013)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2024 Amount Series A - Cour Pharma Valuation Lumira Ventures , Roche
Sep, 2022 Amount Series A - Cour Pharma Valuation Alpha Wave Global
Jan, 2016 Amount Seed - Cour Pharma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cour Pharma

Cour Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Roche and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Lumira Ventures is engaged in life sciences venture capital investment.
Founded Year Domain Location
Venture capital firm focused on growth-stage companies
Founded Year Domain Location
Angelini Ventures is focused on investing in BioTech and Digital Health.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cour Pharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cour Pharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cour Pharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cour Pharma

Cour Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Plasma-based biologics are developed for immune deficiency and infectious diseases.
domain founded_year HQ Location
Therapeutic antibodies for cancer and other diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Cour Pharma

When was Cour Pharma founded?

Cour Pharma was founded in 2013.

Where is Cour Pharma located?

Cour Pharma is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.

Is Cour Pharma a funded company?

Cour Pharma is a funded company, having raised a total of $135.2M across 6 funding rounds to date. The company's 1st funding round was a Seed of $169.25K, raised on Jan 28, 2013.

How many employees does Cour Pharma have?

As of Dec 31, 2021, the latest employee count at Cour Pharma is 31.

What does Cour Pharma do?

Cour Pharma was founded in 2013 and is based in Chicago, United States. Operations focus on the biotechnology sector, where proprietary nanoparticle platforms are utilized for immune-related conditions. Immune Modifying Nanoparticles target severe inflammations by binding to monocytes for elimination, while Tolerizing Immune Modifying Nanoparticles introduce antigens to reprogram the immune system against autoimmune and allergic disorders. The nanoparticles consist of an FDA-approved biodegradable copolymer.

Who are the top competitors of Cour Pharma?

Cour Pharma's top competitors include Moderna, BeiGene and ADMA Biologics.

What products or services does Cour Pharma offer?

Cour Pharma offers CNP-103 and CNP-106.

Who are Cour Pharma's investors?

Cour Pharma has 7 investors. Key investors include Pfizer, Roche, Bristol-Myers Squibb, Lumira Ventures, and Alpha Wave Global.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available